A practical synthesis of multitargeted antifolate LY231514

被引:34
|
作者
Barnett, CJ [1 ]
Wilson, TM [1 ]
Kobierski, ME [1 ]
机构
[1] Lilly Res Labs, Clin Proc Res & Dev Div, Indianapolis, IN 46285 USA
关键词
D O I
10.1021/op9802172
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
A concise and scalable synthesis of LY231514 (1), a new pyrrolo[2,3-d]pyrimidine-based antitumor agent, is presented. Reaction of 2-bromo-4-arylbutanal 9 with 2,4-diamino-6-hydroxypyrimidine (10) regioselectively provided pyrrolo[2,3-d] pyrimidine 11, representing the core structure of the drug, in good yield. Assimilation of the glutamic acid residue by conventional means completed the synthesis. Development of the optimized synthetic route emphasized avoiding isolation of the relatively unstable aldehyde and bromoaldehyde intermediates.
引用
收藏
页码:184 / 188
页数:5
相关论文
共 50 条
  • [31] A phase I and pharmacokinetic (PK) study of the multitargeted antifol (MTA) LY231514 with folic acid (FA)
    Hammond, L
    Baker, SD
    Villalona-Calero, M
    Eckhardt, SG
    Drengler, R
    Aylesworth, C
    Johnson, T
    Hidalgo, M
    Rodriguez, G
    Diab, S
    Monroe, P
    Thornton, D
    Johnson, R
    Von Hoff, D
    Rowinsky, E
    ANNALS OF ONCOLOGY, 1998, 9 : 160 - 160
  • [32] Mechanisms of acquired resistance to the multitargeted antifolate (MTA, LY231514) in human leukemia and colon carcinoma cell lines continuously exposed to stepwise increasing drug concentrations
    Schultz, RM
    Bewley, JR
    Dempsey, JA
    Roberts, EF
    Shih, C
    Chen, VJ
    ANNALS OF ONCOLOGY, 1998, 9 : 154 - 154
  • [33] Expression levels of thymidylate synthase as a predictive marker for tumor susceptibility to the multitargeted antifolate LY231514.
    Zervos, PH
    Roberts, EF
    Dotzlaf, JE
    Chen, VJ
    Schultz, RM
    Seitz, DE
    CLINICAL CANCER RESEARCH, 1999, 5 : 3860S - 3861S
  • [34] Multiple folate enzyme inhibition: Mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA)
    Shih, C
    Habeck, LL
    Mendelsohn, LG
    Chen, VJ
    Schulz, RM
    ADVANCES IN ENZYME REGULATION, VOL 38, 1998, 38 : 135 - 152
  • [35] MTA (LY231514) in advanced carcinoma of the cervix
    Goedhals, L
    van Wijk, AL
    ANNALS OF ONCOLOGY, 1998, 9 : 70 - 71
  • [36] MTA(LY231514) in advanced carcinoma of the cervix
    Goedhals, L
    van Wijk, AL
    ANNALS OF ONCOLOGY, 1998, 9 : 161 - 161
  • [37] SYNTHESIS OF LY288601, A 5,6-DIHYDROPYRROLO[2,3-D]PYRIMIDINE BASED ANTIFOLATE COMPOUND RELATED TO LY231514
    BARNETT, CJ
    WILSON, TM
    HETEROCYCLES, 1993, 35 (02) : 925 - 936
  • [38] A phase II trial of multi-targeted antifolate (MTA) (LY231514) in patients with unresectable pancreatic cancer
    Miller, KD
    Loehrer, PJ
    Picus, J
    Blanke, C
    John, W
    Clark, J
    Schulman, LN
    Burris, H
    Thornton, D
    ANNALS OF ONCOLOGY, 1998, 9 : 46 - 46
  • [39] Quality of life assessments of patients with pancreatic cancer receiving MTA (LY231514, a multi-targeted antifolate)
    Liepa, AM
    Picus, J
    Blanke, C
    John, W
    Clark, J
    Schulman, L
    Burris, A
    Thornton, D
    Loehrer, PJ
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : OP19 - OP19
  • [40] Population pharmacodynamics of LY231514 in patients with cancer.
    Periclou, AP
    Ouellet, D
    Johnson, RD
    Woodworth, JM
    Lalonde, RL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 196 - 196